Sutro Competitors
| STRO Stock | USD 15.52 0.92 6.30% |
Sutro Biopharma vs Kalaris Therapeutics Correlation
Poor diversification
The correlation between Sutro Biopharma and KLRS is 0.67 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Sutro Biopharma and KLRS in the same portfolio, assuming nothing else is changed.
Moving together with Sutro Stock
Moving against Sutro Stock
| 0.93 | ABP | Abpro Holdings | PairCorr |
| 0.86 | DWTX | Dogwood Therapeutics | PairCorr |
| 0.86 | KURA | Kura Oncology | PairCorr |
| 0.76 | LYRA | Lyra Therapeutics | PairCorr |
| 0.71 | GNLX | Genelux Common | PairCorr |
Sutro Biopharma Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Sutro Biopharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Sutro and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Sutro Biopharma does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Sutro Stock performing well and Sutro Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Sutro Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ARTV | 6.48 | 0.58 | 0.06 | (0.58) | 7.44 | 8.00 | 118.69 | |||
| ADVM | 3.39 | 0.49 | 0.09 | (0.96) | 3.70 | 10.34 | 40.97 | |||
| DTIL | 3.00 | (1.01) | 0.00 | (0.95) | 0.00 | 5.64 | 15.28 | |||
| PLRX | 2.64 | (0.58) | 0.00 | 2.65 | 0.00 | 4.58 | 22.72 | |||
| GUTS | 5.12 | (0.79) | 0.00 | (0.94) | 0.00 | 11.89 | 85.71 | |||
| IFRX | 4.72 | (0.66) | 0.00 | (0.19) | 0.00 | 7.84 | 43.11 | |||
| MGX | 3.05 | (0.78) | 0.00 | (0.27) | 0.00 | 6.21 | 18.63 | |||
| CNTB | 4.53 | 0.89 | 0.14 | (0.52) | 4.33 | 11.89 | 38.27 | |||
| STTK | 3.67 | 1.02 | 0.28 | 1.49 | 3.13 | 6.42 | 27.88 | |||
| KLRS | 4.65 | 1.02 | 0.17 | (1.85) | 4.34 | 15.58 | 32.70 |
Cross Equities Net Income Analysis
Compare Sutro Biopharma and related stocks such as Artiva Biotherapeutics, Adverum Biotechnologies, and Precision BioSciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARTV | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (18 M) | (71.8 M) | (58.4 M) | (27.7 M) | (58.5 M) | (52.6 M) | (55.3 M) |
| DTIL | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (21.1 M) | (46 M) | (92.9 M) | (109 M) | (30.6 M) | (111.6 M) | (61.3 M) | 7.2 M | 6.5 M | 6.8 M |
| PLRX | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (20.6 M) | (30.3 M) | (631 K) | (39.7 M) | (17.9 M) | (123.3 M) | (161.3 M) | (210.3 M) | (189.3 M) | (179.8 M) |
| GUTS | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.5 M) | (38.7 M) | (46.5 M) | (77.1 M) | (68.7 M) | (68.7 M) | (61.8 M) | (64.9 M) |
| IFRX | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (4.9 M) | (8.9 M) | (24.2 M) | (29.8 M) | (59.6 M) | (38.7 M) | (53.9 M) | (31 M) | (42.7 M) | (46.1 M) | (41.5 M) | (43.5 M) |
| MGX | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (21.4 M) | (43.6 M) | (68.3 M) | (78.1 M) | (78.1 M) | (70.3 M) | (73.8 M) |
| CNTB | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (120.3 M) | (205.2 M) | (116.4 M) | (59.5 M) | (15.6 M) | (18 M) | (18.9 M) |
| STTK | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (24 M) | (35.4 M) | (45 M) | (100.6 M) | (87.3 M) | (75.4 M) | (67.9 M) | (71.3 M) |
| KLRS | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (2.4 M) | (23.8 M) | (69.8 M) | (172 M) | (15.5 M) | (14.7 M) | (58.8 M) | (52.9 M) | (55.5 M) |
Sutro Biopharma and related stocks such as Artiva Biotherapeutics, Adverum Biotechnologies, and Precision BioSciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Sutro Biopharma financial statement analysis. It represents the amount of money remaining after all of Sutro Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Sutro Biopharma Competitive Analysis
The better you understand Sutro Biopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Sutro Biopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Sutro Biopharma's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Sutro Biopharma Competition Performance Charts
Five steps to successful analysis of Sutro Biopharma Competition
Sutro Biopharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Sutro Biopharma in relation to its competition. Sutro Biopharma's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Sutro Biopharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Sutro Biopharma's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Sutro Biopharma, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Sutro Biopharma position
In addition to having Sutro Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Real Estate Thematic Idea Now
Real Estate
Publicly traded companies that are involved in real estate development, property maintenance and management of real estate investment trusts (REIT) funds. The Real Estate theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Sutro Biopharma Correlation with its peers. To learn how to invest in Sutro Stock, please use our How to Invest in Sutro Biopharma guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Biotechnology sector continue expanding? Could Sutro diversify its offerings? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sutro Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.60) | Revenue Per Share | Quarterly Revenue Growth 0.138 | Return On Assets | Return On Equity |
Understanding Sutro Biopharma requires distinguishing between market price and book value, where the latter reflects Sutro's accounting equity. The concept of intrinsic value - what Sutro Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Sutro Biopharma's price substantially above or below its fundamental value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Sutro Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.